nbDMARD N=48 | Anti-TNF N=190 | |
---|---|---|
Person-years of follow-up (per year) | 159 | 893 |
Median follow-up per subject; years (IQR) | 3.9 (1.9, 4.9) | 5.2 (3.3, 6.6) |
Mean age (SD) | 51.9 (8.6) | 49.8 (9.8) |
Ever smoked; number (%) | 38 (79) | 139 (73) |
Median disease duration; years (IQR) | 4.5 (1.0, 14.5) | 10.0 (5.0, 16.5) |
Mean DAS28 score (SD) | 5.2 (1.3) | 6.6 (0.9) |
Median number prior nbDMARD (IQR) | 2.0 (1.0, 3.5) | 4.0 (3.0, 5.0) |
CIS cervix recorded on consultant baseline form; N (%) | 7 (15) | 21 (11) |
Median time from prior CIS cervix to registration; years (IQR) | 14 (9, 19) | 13 (8, 17) |
Incident female genital cancer: N | 2 | 0 |
Incident female genital cancer: rate per 1000/year (95% CI) | 13 (2, 45) | 0 (0, 4.1)* |
*One-sided 97.5% CI.
CIS, carcinoma in situ; DAS, disease activity score; nbDMARD, non-biologic disease modifying antirheumatic therapy; TNF, tumour necrosis factor.